March Sales at Wholly-Owned Subsidiary Mesa Pharmacy Exceed $8.8M

Praxsyn

John F. Garbino and Edward Kurtz Join Board of Directors

Praxsyn Name Change Imminent

PALO ALTO, Calif., April 9, 2014 (GLOBE NEWSWIRE) -- The PAWS Pet Company, Inc. (OTCQB:PAWS), announced it completed the merger of Pharmacy Development Corp. (PDC), the parent company of Mesa Pharmacy, Inc. ("MESA") into PDC, Inc. (PDCINC), PAWS wholly-owned subsidiary on March 31, 2014.

During the month of March, filled and shipped prescriptions gross revenues are exceeded $8,800,000 and the Company believes that MESA is on track to easily exceed that number in April.

MESA focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and clinics. MESA has developed a series of topical ointments, in different strengths, that provide the pain relief doctors seek.

Furthermore, and also on March 31, 2014, the Board of Directors voted to add John F. Garbino and Edward Kurtz to the Board of Directors.

Edward is the current COO of PDC, INC., and of MESA. Today PDCINC and MESA employ over 25 people with first quarter 2014 sales (unaudited) exceeding $20,000,000.

John F. Garbino is currently the CEO of Trestles Pain Management ("Trestles"), a privately held pharmaceutical management consulting company. John and Trestles have spurred the rapid growth in sales MESA has experienced during 2014 and John intends to help grow sales at an ever-increasing rate and expand MESA's business into the rest of the nation.

Finally, a shareholder consent regarding the change of the corporate name to Praxsyn Corporation was completed on March 26, 2014. The Company expects to file amended articles of incorporation in the next few days, and when finalized, intends to submit the necessary paperwork to change its name with all relevant regulatory bodies.

About The PAWS Pet Company, Inc.

The PAWS Pet Company, Inc. is undergoing a transition from the pet space to the pharmaceutical space. This exciting transition strategy has been developed to take advantage of the changes underway in traditional medical services. PAWS believes that great opportunities exist in pharmaceuticals and how they are delivered to the public.

For more information on The PAWS Pet Company go to www.thepawspetcompany.com. For more information on Pharmacy Development Inc. go to www.pharmacydevelopment.com

Company Contact: ir@thepawspetcompany.com

Forward-Looking Statements

Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC

Source: Praxsyn